{"source_content":"请务必阅读正文之后的信息披露和重要声明公司研究公司点评报告证券研究报告＃industryId＃休闲服务＃investSuggestion＃审慎增持(维持）＃marketData＃市场数据市场数据日期2020-03-30收盘价（元）158.42总股本（百万股）480.00流通股本（百万股）93.34总市值（百万元）76041.6流通市值（百万元）14787.23净资产（百万元）5,018.14总资产（百万元）5,716.89每股净资产10.45＃relatedReport＃相关报告《透明质酸新食品原料获批，公司迎新增长点》2021-01-10《站稳原料&助力化妆品，三架马车共促未来健康发展》2020-10-30《透明质酸行业报告-驶确定性优赛道，享稳定性高增速》2020-01-12＃emailAuthor＃分析师：刘嘉仁liujr@xyzq.com.cnS0190518080001研究助理：周子莘zhouzixin@xyzq.com.cn＃assAuthor＃主要财务指标＄zycwzb|主要财务指标＄会计年度20202021E2022E2023E营业收入(百万元)2633388754967382同比增长(%)40%48%41%34%净利润(百万元)64677511741655同比增长(%)10%20%51%41%毛利率(%)81.4%81.3%81.3%81.8%净利润率(%)24.5%19.9%21.4%22.4%净资产收益率（%）12.9%13.4%16.9%19.2%每股收益(元)1.351.622.453.45每股经营现金流(元)1.472.302.073.01投资要点＃summary＃⚫摘要请在该此处表格内输入。⚫⚫说明：投资要点应包括公司基本特点、主要业务看点、研究员的投资逻辑和推荐依据、业绩预期、投资评级、估值分析、风险提示等核心内容。要点应区分先后次序，重要的放在前面。要点3-5个，总字数不超过1000字。风险提示：sr⚫事件：2020年实现营收26.33亿元，同比增长39.63%；归属于上市公司股东的净利润为6.46亿元，同比增长10.29%；扣非归母净利润5.68亿元，同比增长0.13%。Q4实现营收10.36亿元，同比增长73.38%，归母净利润2.08亿元，同比增长22.98%，扣非归母净利润1.94亿元，同比增长25.38%。⚫公司2020年度营收同比增长39.63%至26.33亿元。1）功能性护肤品同比增长112.17%至13.46亿元，占比51.15%。其中润百颜/夸迪分别增长65.29%/513.29%至5.65/3.91亿元。2）原料受海外疫情影响同比下滑7.55%至7.03亿元，但值得注意的是其他生物活性物原料收入同比增长约30%，体现公司原料研发、原料大规模量产能力可复制的优势。3）医疗终端业务同比增长17.82%至5.76亿元，占比21.88%。其中皮肤类医疗产品下半年推出娃娃针，推动收入同比增长9.70%至4.35亿元;骨科注射液产品实现收入0.90亿元，同比增长10.44%;疫情期间新增消杀产品实现收入0.51亿元。⚫2020年归母净利润同比增长10.29%至6.46亿元，增速不及营收源于销售费用高增。化妆品发展元年，公司1）加大营销投放，通过央视广告、薇娅/李佳琦直播、自建直播团队和MCN机构合作强化品牌力，提高消费者转化率，2）销售费用增长带动销售收入的快速增长，功能性护肤品业绩增长迅速，销售人员奖金增加。预计未来各品牌销售额达到一定规模后，销售费用投入会有所降低。⚫公司未来发展：围绕原料优势，继续完善下游产业链，打造完整生态圈。①原料上积极探索植物发酵、绿色表面活性剂等新发酵原料研发；②医美产品继续推动新品注册，同时有望于21年年中推出全新润致填充产品；③大力发展功能性消费品，推动护肤品和食品及其他生活用品发展，目前护肤品口碑模式已然开启，期待护肤品持续高速发展和食品发力形成新增长点。⚫投资建议：公司以大规模低成本量产原料为优势，并围绕优势原料向下游布局。1）食品原料获批有望为公司提供新增量，2）化妆品行业的快速增长也为上游细分赛道的龙头原料供应商华熙生物提供确定性增长机会。调整21-23年EPS为1.62/2.45/3.45元，对应2021年3月30日收盘价的PE为98/65/46x。风险提示：医疗美容产品审批加严，海外疫情暂时难以缓解，食品推出不达预期。＃dyCompany＃华熙生物＃dyStockcode＃688363＃title＃收入表现较好，预期未来注重投放效率提升净利率＃createTime1＃2021年03月31日请务必阅读正文之后的信息披露和重要声明-2-公司点评报告(带市场行情)报告正文事件公司公告，2020年实现营收26.33亿元，同比增长39.63%；归属于上市公司股东的净利润为6.46亿元，同比增长10.29%；扣非归母净利润5.68亿元，同比增长0.13%。Q4实现营收10.36亿元，同比增长73.38%，归母净利润2.08亿元，同比增长22.98%，扣非归母净利润1.94亿元，同比增长25.38%。点评公司2020年度营收同比增长39.63%至26.33亿元。Q4实现营收10.36亿元，同比增长73.38%，营收逐季加速增长。分拆来看：1)功能性护肤品同比增长112.17%至13.46亿元，占比51.15%。润百颜/夸迪/米蓓尔/BM肌活品牌分别增长65.29%/513.29%/136.32%/45.71%至5.65/3.91/1.99/1.13亿元。公司积极发展线上渠道，充分利用全领域流量与多元化渠道，对各品牌进行差异化定位满足长尾用户需求，不断推出爆款获得市场关注度与认可度。①短期事件使得化妆品线上消费进一步养成；②润百颜8月推出新品377小灯管精华次抛玻尿酸，与多个KOL合作，并在通过薇娅直播间打开知名度，新品上市后在8月和11月成为天猫旗舰销售额排名第一的产品，爬取的天猫数据显示377精华在两个月中分别实现销售额1890/3197万元；③夸迪/米蓓尔基数较低，增速较快。2)原料业务部分同比下滑7.55%至7.03亿元，占比26.73%。原料产品包括透明质酸、γ-氨基丁酸、熙安颜依克多因、Hyafactor®-PGA聚谷氨酸钠等其他生物活性物质。一季度受到国内疫情影响，后续季度受到海外疫情影响，整体营收略有下滑。但值得注意的是其他生物活性物原料业务收入同比增长约30%，进一步体现公司原料研发、原料大规模量产能力可复制的优势。3)医疗终端业务同比增长17.82%至5.76亿元，占比21.88%。皮肤类医疗产品实现收入4.35亿元，同比增长9.70%；骨科注射液产品实现收入0.90亿元，同比增长10.44%;其他产品实现收入0.51亿元，同比增长378.16%。在国内疫情趋缓时，公司充分利用需求反弹机会实现销售快速恢复。①医美业务上，2020年新增注册产品注射用交联透明质酸钠凝胶、注射用交联透明质酸钠凝胶(粒径II)、注射用交联透明质酸钠凝胶(粒径III)。虽前期受制于疫情影响，但公司通过美团、天猫等线上平台实现线上、线下全域流量打通，保持产品的市热度，并于下半年推出微交联的娃娃针，全年实现正增长；②骨科产品上，公司加大在区域的招投标及渠道铺设，发挥品牌优势推进全国骨科学术交流。请务必阅读正文之后的信息披露和重要声明-3-公司点评报告(带市场行情)图1、2020年全年营收同比增速为39.63%图2、2020年全年归母净利润同比增速为10.29%数据来源：公司公告，兴业证券经济与金融研究院整理数据来源：公司公告，兴业证券经济与金融研究院整理图3、20Q4营收同比增速为73.37%图4、20Q4归母净利润同比增速为22.98%数据来源：公司公告，兴业证券经济与金融研究院整理数据来源：公司公告，兴业证券经济与金融研究院整理图5、2020年各护肤品品牌不同渠道销售量占比资料来源：公司公告，兴业证券经济与金融研究院整理0%10%20%30%40%50%60%0.05.010.015.020.025.030.02017201820192020营业收入（亿元，左轴）YOY（右轴）-40%-20%0%20%40%60%80%100%0.01.02.03.04.05.06.07.02017201820192020归母净利润（亿元，左轴）YOY（右轴）0%10%20%30%40%50%60%70%80%0246810122018Q42019Q42020Q4营业收入（亿元，左轴）YOY（右轴）0%10%20%30%40%50%60%70%0.00.51.01.52.02.52018Q42019Q42020Q4归母净利润（亿元，左轴）YOY（右轴）0%10%20%30%40%50%60%70%80%90%100%润百颜夸迪米蓓尔BM肌活其他渠道经销渠道天猫渠道请务必阅读正文之后的信息披露和重要声明-4-公司点评报告(带市场行情)图6、第三方数据显示，护肤品三季度实现近5倍增长，10月实现10倍以上增长资料来源：第三方监测数据，兴业证券经济与金融研究院整理表1、华熙原料产品明细原料产品应用领域产品类别产品名称产品应用透明质酸医药滴眼液级Hyature®玻璃酸钠滴眼液，外用药物等注射级Hyature®玻璃酸钠软组织填充剂等医疗器械级Hyature®玻璃酸钠伤口愈合外用制剂化妆品透明质酸钠Hybloom®透明质酸钠天然保湿因子纳诺HA®酶切寡聚透明质酸钠透皮吸收，深层保湿透明质酸钠衍生物Hyacolor®油分散透明质酸钠保湿滋润cationHA®高亲和性透明质酸钠高亲和性，耐冲洗，Hymagic®-AcHA乙酰化透明质酸钠高吸肤性，双倍保湿力Hyacross®透明质酸弹性体隐形防护，抵御紫外线熙敏修TM超活透明质酸抑制炎症因子释放食品HAPLEX®透明质酸钠改善皮肤水份，增加骨密度新领域Biomoist®透明质酸（口腔专用）保湿、润滑HyadomTM透明质酸润滑液润滑、保湿、滋养HYAPETTM透明质酸钠润滑、营养其他生物活性物质γ-氨基丁酸天然抗衰老因子熙安颜TM依克多因抗压防护，舒缓修护Hyafactor®-PGA聚谷氨酸钠促进天然保湿因子蓄积Hyafactor®-SG小核菌胶水凝胶增强皮肤屏障纳豆提取液保护皮肤屏障，多重保湿糙米发酵滤液提高细胞活力；麦角硫因防止紫外线辐射损伤资料来源：公司公告，兴业证券经济与金融研究院2020年归母净利润同比增长10.29%至6.46亿元，增速不及营收源于销售费用高增，但利润增速较上半年较大提升：➢毛利率：较去年同期提升1.75pct：1)原料业务：毛利率水平最低，营收占比有所下降。公司通过不断科研构筑高壁垒并保持产品竞争力，毛利率为78.09%，同比增长1.97%。其中，医药级透明质酸原料毛利率保持在90%左右。2)医疗终端业务：毛利率为84.55%，毛利率水平最高但20年有所下降，营收上升但不及护肤品，因此营收占比同比下降。公司正式推出拥有微交联技术及利多卡因缓释技术的润致“娃娃针”产品，该产品拥有三类医疗器械证书，具0%10000%20000%30000%40000%50000%60000%-500%0%500%1000%1500%2000%2500%3000%3500%润百颜（左轴）Medrepair（左轴）德玛润（左轴）BIO-MESO（左轴）功能性护肤品合计（左轴）夸迪(右轴）请务必阅读正文之后的信息披露和重要声明-5-公司点评报告(带市场行情)有核心市场竞争力。3)功能性护肤品业务：毛利率为81.89%，毛利率水平相对较高并逐步增长，营收占比增长迅速。其中，润百颜/夸迪/米蓓尔/BM肌活品牌的毛利率分别同比提高+2.80%/+5.95%/-0.53%/+9.82%。➢化妆品发展元年，销售费用率增长14.1pct带动期间费用率增长11.6pct：1）销售费用：20年销售费用10.99亿，销售费用率同比增长14.1pct，通过销售费用投放实现自TOB端向TOC端转型。公司发生广告宣传费用共计1.25亿元，线上推广服务费共计4.93亿元。1）化妆品发展元年，公司在继续加大研发投入，提升技术力和产品力的同时，通过央视广告、薇娅/李佳琦直播、自建直播团队和MCN机构合作强化品牌力，提高消费者转化率，提升功能性护肤品营收，2）销售费用增长带动销售收入的快速增长，功能性护肤品业绩增长迅速，销售人员奖金增加。预计未来各品牌销售额达到一定规模后，销售费用投入会有所降低。2）管理费用：同比下降3.51pct。管理费用的变化主要由于：①Revitacare业绩对赌协议于2019年已完成，2020年不需要计提业绩奖励，导致本期计入管理费用的职工薪酬有所减少；②受全球疫情影响，线下业务推广与交流减少，会议费、差旅费等运营费用减少。3）研发费用：同比增长0.38pct。公司通过研发提升科技护城河，1）研发人员数量增加98人，研发人员占比提升自19年的16.76%提升至20年的18.1%；2）为保护研发成果，公司申请知识产权等服务费用增加。4）2020年获7761.3万元非经常性损益，较上一年增加5950万元。其中5286.9万元来源于政府补贴，4014.1万元来源于委托他人投资或管理资产损益。图6、毛利率保持增长趋势，净利率有所下降图7、销售费用投放实现自TOB端向TOC端转型数据来源：公司公告，兴业证券经济与金融研究院整理数据来源：公司公告，兴业证券经济与金融研究院整理0%10%20%30%40%50%60%70%80%90%毛利率净利率20162017201820192020-5%0%5%10%15%20%25%30%35%40%45%销售费用率研发费用率管理费用率财务费用率20162017201820192020请务必阅读正文之后的信息披露和重要声明-6-公司点评报告(带市场行情)图8、功能性护肤品营收占比增长迅速图9、护肤品毛利率有所提升数据来源：公司公告，兴业证券经济与金融研究院整理数据来源：公司公告，兴业证券经济与金融研究院整理图10、Q4公司单季度净利率有所回升图11、Q4销售费用率较Q3季度增长2.21pct数据来源：公司公告，兴业证券经济与金融研究院整理数据来源：公司公告，兴业证券经济与金融研究院整理存货周转天数较去年同期较高，但环比改善。原材料&产品备货导致年末存货较年初增加51.59%。一方面海外疫情导致原料出货不及预期，另一方面，公司今年是化妆品元年，产品和原材料的大量备货使得库存稍有挤压，但环比明显改善。0%10%20%30%40%50%60%70%80%90%100%20162017201820192020原料产品医疗终端产品功能性护肤品其他收入0%10%20%30%40%50%60%70%80%90%100%原料产品毛利率医疗终端产品毛利率功能性护肤品毛利率201620172018201920200%10%20%30%40%50%60%70%80%90%100%毛利率净利率2020Q12020Q22020Q32020Q40%5%10%15%20%25%30%35%40%45%50%销售费用率研发费用率2020Q12020Q22020Q32020Q4请务必阅读正文之后的信息披露和重要声明-7-公司点评报告(带市场行情)图12、备货导致20年度存货周转天数提升，但环比有所改善（天）资料来源：wind，兴业证券经济与金融研究院整理公司未来发展：围绕原料优势，继续完善下游产业链，打造完整生态圈1）原料产品：维持传统玻尿酸原料优势的前提下，积极研发多种生物活性物，拓展其应用领域，积极探索植物发酵、绿色表面活性剂等新发酵原料研发，针对在医药、化妆品和食品领域应用广泛的多个功能糖及氨基酸类物质，开展合成生物学关键技术及产业转化研究，构建微生物细胞工厂、酶催化体系等并实现工程化应用，取代传统的动植物提取及化学合成法。2）医美产品：加快医美产品管线布局和产品升级迭代，推动针对中面部、唇部等不同适应症产品注册工作，21年年中有望推出全新润致填充产品；3）个人健康消费品：①护肤品：继续推动现有的护肤品品牌发展，进一步推动整合运营能力。公司目前123项在研项目中与化妆品相关有14项，值得注意的是公司已经开始布局功效测评体系，符合当前化妆品监管趋势。②2021年公司已推出透明质酸饮品品牌“水肌泉”和食品终端品牌“黑零”，未来将加快发展食品终端业务，推进透明质酸市场应用教育。根据我们此前报告测算，成熟期食品原料和终端产品可为公司贡献32-141亿收入，4.8-20.1亿净利润，相比2020年26.33/7.57亿的营收/净利润还有较大增量空间，但公司的发展节奏仍需考虑公司经营策略和市场实际情况；③其他应用场景：未来公司将积极拓展不同应用场景，包括母婴、计生、日用消费品等领域，有助于进一步建立品牌形象，强化品牌认知，降低获客成本和销售费用。2021年护肤品数据显示公司前期投放初见成效，口碑模式已然开启。第三方销售数据显示，润百颜1/2月同比增速超过400%/200%至4013/2762万元，与此同时第二品牌夸迪在资源投放不及润百颜的情况下，实现反超过，前两月GMV为润0501001502002503003504002019Q12019Q22019Q32019Q42020Q12020Q22020Q32020Q4存货周转天数请务必阅读正文之后的信息披露和重要声明-8-公司点评报告(带市场行情)百颜的1.9倍，预计夸迪发力主要源于消费者的口碑相传，进一步体现出公司的较强产品力。投资建议：公司以大规模低成本量产原料为优势，并围绕优势原料向下游布局。1）食品原料获批有望为公司提供新增量，2）化妆品行业的快速增长也为上游细分赛道的龙头原料供应商华熙生物提供确定性增长机会。调整21-23年EPS为1.62/2.45/3.45元，对应2021年3月30日收盘价的PE为98/65/46x。风险提示：医疗美容产品审批加严，海外疫情暂时难以缓解，食品推出不达预期。请务必阅读正文之后的信息披露和重要声明-9-公司点评报告(带市场行情)/附表资产负债表单位:百万元利润表单位:百万元会计年度20202021E2022E2023E会计年度20202021E2022E2023E流动资产3664443358347732营业收入2633388754967382现金1390280638045362营业成本48972610261341应收账款3726268501157营业税金及附加34507197其他应收款35396180营业费用1099161622573018预付账款456895124管理费用162479590718存货477372398402财务费用-1-41-47-52其他流动资产1345522626607资产减值损失-16222非流动资产2053189418171700公允价值变动收益3455长期投资18000投资净收益34303530固定资产627860916883营业利润75791113841956无形资产427427427427营业外收入5555其他非流动资产982607475390营业外支出3222资产总计5717632776519432利润总额75991413871959流动负债553447590706所得税114139212304短期借款24000净利润64577511741655应付账款197255378486少数股东损益-1-1-1-1其他流动负债332192212221归属母公司净利润64677511741655非流动负债1468897110EBITDA83294614352014长期借款0000EPS（元）1.351.622.453.45其他非流动负债1468897110负债合计699535687816主要财务比率少数股东权益-2-2-3-3会计年度20192020E2021E2022E股本480480480480成长能力资本公积3452345234523452营业收入39.6%47.7%41.4%34.3%留存收益1088186430364689营业利润8.2%20.4%51.8%41.4%归属母公司股东权益5020579469668619归属于母公司净利润10.3%20.0%51.5%41.0%负债和股东权益5717632776519432获利能力毛利率(%)81.4%81.3%81.3%81.8%现金流量表单位:百万元净利率(%)54.8%54.8%24.5%19.9%会计年度20202021E2022E2023EROE(%)12.9%13.4%16.9%19.2%经营活动现金流70511069931446ROIC(%)23.0%30.8%45.6%61.4%净利润64577511741655偿债能力折旧摊销757698110资产负债率(%)12.2%8.4%9.0%8.7%财务费用-1-41-47-52净负债比率(%)3.45%0.00%0.00%0.00%投资损失-34-30-35-30流动比率6.639.939.8810.95营运资金变动25307-177-259速动比率5.769.099.2110.38其他经营现金流-519-2023营运能力投资活动现金流-1331293-4162总资产周转率0.490.650.790.86资本支出763000应收账款周转率7877长期投资11-1800应付账款周转率3.353.213.253.11其他投资现金流-558276-4162每股指标（元）筹资活动现金流-160174550每股收益(最新摊薄)1.351.622.453.45短期借款24-2400每股经营现金流(最新摊薄)1.472.302.073.01长期借款0000每股净资产(最新摊薄)10.4612.0714.5117.96普通股增加0000估值比率资本公积增加0000P/E117.7498.0864.7545.94其他筹资现金流-184414550P/B15.1513.1210.928.82现金净增加额-79814169971558EV/EBITDA89785137请务必阅读正文之后的信息披露和重要声明-10-公司点评报告(带市场行情)分析师声明本人具有中国证券业协会授予的证券投资咨询执业资格并注册为证券分析师，以勤勉的职业态度，独立、客观地出具本报告。本报告清晰准确地反映了本人的研究观点。本人不曾因，不因，也将不会因本报告中的具体推荐意见或观点而直接或间接收到任何形式的补偿。投资评级说明投资建议的评级标准类别评级说明报告中投资建议所涉及的评级分为股票评级和行业评级（另有说明的除外）。评级标准为报告发布日后的12个月内公司股价（或行业指数）相对同期相关证券市场代表性指数的涨跌幅。其中：A股市场以上证综指或深圳成指为基准，香港市场以恒生指数为基准；美国市场以标普500或纳斯达克综合指数为基准。股票评级买入相对同期相关证券市场代表性指数涨幅大于15%审慎增持相对同期相关证券市场代表性指数涨幅在5%～15%之间中性相对同期相关证券市场代表性指数涨幅在-5%～5%之间减持相对同期相关证券市场代表性指数涨幅小于-5%无评级由于我们无法获取必要的资料，或者公司面临无法预见结果的重大不确定性事件，或者其他原因，致使我们无法给出明确的投资评级行业评级推荐相对表现优于同期相关证券市场代表性指数中性相对表现与同期相关证券市场代表性指数持平回避相对表现弱于同期相关证券市场代表性指数信息披露本公司在知晓的范围内履行信息披露义务。客户可登录www.xyzq.com.cn内幕交易防控栏内查询静默期安排和关联公司持股情况。使用本研究报告的风险提示及法律声明兴业证券股份有限公司经中国证券监督管理委员会批准，已具备证券投资咨询业务资格。本报告仅供兴业证券股份有限公司（以下简称“本公司”）的客户使用，本公司不会因接收人收到本报告而视其为客户。本报告中的信息、意见等均仅供客户参考，不构成所述证券买卖的出价或征价邀请或要约。该等信息、意见并未考虑到获取本报告人员的具体投资目的、财务状况以及特定需求，在任何时候均不构成对任何人的个人推荐。客户应当对本报告中的信息和意见进行独立评估，并应同时考量各自的投资目的、财务状况和特定需求，必要时就法律、商业、财务、税收等方面咨询专家的意见。对依据或者使用本报告所造成的一切后果，本公司及/或其关联人员均不承担任何法律责任。本报告所载资料的来源被认为是可靠的，但本公司不保证其准确性或完整性，也不保证所包含的信息和建议不会发生任何变更。本公司并不对使用本报告所包含的材料产生的任何直接或间接损失或与此相关的其他任何损失承担任何责任。本报告所载的资料、意见及推测仅反映本公司于发布本报告当日的判断，本报告所指的证券或投资标的的价格、价值及投资收入可升可跌，过往表现不应作为日后的表现依据；在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告；本公司不保证本报告所含信息保持在最新状态。同时，本公司对本报告所含信息可在不发出通知的情形下做出修改，投资者应当自行关注相应的更新或修改。除非另行说明，本报告中所引用的关于业绩的数据代表过往表现。过往的业绩表现亦不应作为日后回报的预示。我们不承诺也不保证，任何所预示的回报会得以实现。分析中所做的回报预测可能是基于相应的假设。任何假设的变化可能会显著地影响所预测的回报。本公司的销售人员、交易人员以及其他专业人士可能会依据不同假设和标准、采用不同的分析方法而口头或书面发表与本报告意见及建议不一致的市场评论和/或交易观点。本公司没有将此意见及建议向报告所有接收者进行更新的义务。本公司的资产管理部门、自营部门以及其他投资业务部门可能独立做出与本报告中的意见或建议不一致的投资决策。本报告并非针对或意图发送予或为任何就发送、发布、可得到或使用此报告而使兴业证券股份有限公司及其关联子公司等违反当地的法律或法规或可致使兴业证券股份有限公司受制于相关法律或法规的任何地区、国家或其他管辖区域的公民或居民，包括但不限于美国及美国公民（1934年美国《证券交易所》第15a-6条例定义为本「主要美国机构投资者」除外）。本报告的版权归本公司所有。本公司对本报告保留一切权利。除非另有书面显示，否则本报告中的所有材料的版权均属本公司。未经本公司事先书面授权，本报告的任何部分均不得以任何方式制作任何形式的拷贝、复印件或复制品，或再次分发给任何其他人，或以任何侵犯本公司版权的其他方式使用。未经授权的转载，本公司不承担任何转载责任。特别声明在法律许可的情况下，兴业证券股份有限公司可能会持有本报告中提及公司所发行的证券头寸并进行交易，也可能为这些公司提供或争取提供投资银行业务服务。因此，投资者应当考虑到兴业证券股份有限公司及/或其相关人员可能存在影响本报告观点客观性的潜在利益冲突。投资者请勿将本报告视为投资或其他决定的唯一信赖依据。兴业证券研究上海北京深圳地址：上海浦东新区长柳路36号兴业证券大厦15层邮编：200135邮箱：research@xyzq.com.cn地址：北京西城区锦什坊街35号北楼601-605邮编：100033邮箱：research@xyzq.com.cn地址：深圳市福田区皇岗路5001号深业上城T2座52楼邮编：518035邮箱：research@xyzq.com.cn","data":[{"id":"1","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"2020年实现营收26.33亿元，","content_offset":["835","852"],"indicators":[{"indicator_name":"营业收入","indicator_value":["26.33亿元","844","851"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长39.63%","content_offset":["852","862"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["39.63%","856","862"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"扣非归母净利润5.68亿元","content_offset":["895","908"],"indicators":[{"indicator_name":"扣非归母净利润 ","indicator_value":["6.46亿元","877","883"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长0.13%","content_offset":["909","918"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["10.29%","888","894"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"Q4实现营收10.36亿元","content_offset":["919","932"],"indicators":[{"indicator_name":"营业收入","indicator_value":["10.36亿元","925","932"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长73.38%","content_offset":["933","943"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["73.38%","937","943"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"归母净利润2.08亿元","content_offset":["944","955"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.08亿元","949","955"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长22.98%","content_offset":["956","966"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["22.98%","960","966"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"扣非归母净利润1.94亿元","content_offset":["967","980"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["1.94亿元","974","980"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长25.38%","content_offset":["981","991"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["25.38%","985","991"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"公司2020年度营收同比增长39.63%至26.33亿元","content_offset":["993","1021"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["39.63%","1007","1013"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","995","1000"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"公司2020年度营收同比增长39.63%至26.33亿元","content_offset":["993","1021"],"indicators":[{"indicator_name":"营业收入","indicator_value":["26.33亿元","1014","1021"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","995","1000"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"功能性护肤品同比增长112.17%至13.46亿元","content_offset":["1024","1049"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["112.17%","1034","1041"],"indicator_element":{"产品":["功能性护肤品","1024","1030"],"时间":["2020年","995","1000"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"功能性护肤品同比增长112.17%至13.46亿元","content_offset":["1024","1049"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["13.46亿元","1042","1049"],"indicator_element":{"产品":["功能性护肤品","1024","1030"],"时间":["2020年","995","1000"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"占比51.15%。","content_offset":["1050","1059"],"indicators":[{"indicator_name":"主营业务收入占比","indicator_value":["51.15%","1052","1058"],"indicator_element":{"产品":["功能性护肤品","1024","1030"],"时间":["2020年","995","1000"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"其中润百颜/夸迪分别增长65.29%/513.29%至5.65/3.91亿元","content_offset":["1059","1097"],"indicators":[{"indicator_name":"主营业务收入同比","indicator_value":["65.29%","1071","1077"],"indicator_element":{"品牌":["润百颜","1061","1064"],"时间":["2020年","995","1000"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"其中润百颜/夸迪分别增长65.29%/513.29%至5.65/3.91亿元","content_offset":["1059","1097"],"indicators":[{"indicator_name":"主营业务收入同比","indicator_value":["513.29%","1078","1085"],"indicator_element":{"品牌":["夸迪","1065","1067"],"时间":["2020年","995","1000"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"其中润百颜/夸迪分别增长65.29%/513.29%至5.65/3.91亿元","content_offset":["1059","1097"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["","1059","1059"],"indicator_element":{"品牌":["润百颜","1061","1064"],"时间":["2020年","995","1000"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"其中润百颜/夸迪分别增长65.29%/513.29%至5.65/3.91亿元","content_offset":["1059","1097"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["3.91亿元","1091","1097"],"indicator_element":{"品牌":["夸迪","1065","1067"],"时间":["2020年","995","1000"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"原料受海外疫情影响同比下滑7.55%至7.03亿元","content_offset":["1100","1125"],"indicators":[{"indicator_name":"主营业务收入同比","indicator_value":["7.55%","1113","1118"],"indicator_element":{"上游":["原料","1100","1102"],"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"原料受海外疫情影响同比下滑7.55%至7.03亿元","content_offset":["1100","1125"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["7.03亿元","1119","1125"],"indicator_element":{"上游":["原料","1100","1102"],"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"但值得注意的是其他生物活性物原料收入同比增长约30%","content_offset":["1126","1152"],"indicators":[{"indicator_name":"主营业务同比","indicator_value":["30%","1149","1152"],"indicator_element":{"上游":["生物活性物原料","1135","1142"],"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"医疗终端业务同比增长17.82%至5.76亿元","content_offset":["1180","1203"],"indicators":[{"indicator_name":"主营业务同比","indicator_value":["17.82%","1190","1196"],"indicator_element":{"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"],"业务":["医疗终端业务","1180","1186"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"医疗终端业务同比增长17.82%至5.76亿元","content_offset":["1180","1203"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["5.76亿元","1197","1203"],"indicator_element":{"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"],"业务":["医疗终端业务","1180","1186"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"占比21.88%","content_offset":["1204","1212"],"indicators":[{"indicator_name":"主营业务收入占比","indicator_value":["21.88%","1206","1212"],"indicator_element":{"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"],"业务":["医疗终端业务","1180","1186"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"其中皮肤类医疗产品下半年推出娃娃针，推动收入同比增长9.70%至4.35亿元","content_offset":["1213","1251"],"indicators":[{"indicator_name":"主营业务收入同比","indicator_value":["9.70%","1239","1244"],"indicator_element":{"产品":["皮肤类医疗产品","1215","1222"],"时间":["下半年","1222","1225"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"其中皮肤类医疗产品下半年推出娃娃针，推动收入同比增长9.70%至4.35亿元","content_offset":["1213","1251"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["4.35亿元","1245","1251"],"indicator_element":{"产品":["皮肤类医疗产品","1215","1222"],"时间":["下半年","1222","1225"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"骨科注射液产品实现收入0.90亿元，同比增长10.44%","content_offset":["1252","1280"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["0.90亿元","1263","1269"],"indicator_element":{"产品":["骨科注射液","1252","1257"],"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"骨科注射液产品实现收入0.90亿元，同比增长10.44%","content_offset":["1252","1280"],"indicators":[{"indicator_name":"主营业务收入同比","indicator_value":["10.44%","1274","1280"],"indicator_element":{"产品":["骨科注射液","1252","1257"],"时间":["2020年","1303","1308"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"疫情期间新增消杀产品实现收入0.51亿元","content_offset":["1281","1301"],"indicators":[{"indicator_name":"营业收入","indicator_value":["0.51亿元","1295","1301"],"indicator_element":{"产品":["消杀产品","1287","1291"],"时间":["疫情期间","1281","1285"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"2020年归母净利润同比增长10.29%至6.46亿元","content_offset":["1303","1330"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["6.46亿元","1324","1330"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","1303","1308"]},"indicator_supplement":{"属性":""}}]},{"id":"32","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"2020年归母净利润同比增长10.29%至6.46亿元","content_offset":["1303","1330"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["10.29%","1317","1323"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","1303","1308"]},"indicator_supplement":{"属性":""}}]},{"id":"33","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"调整21-23年EPS为1.62/2.45/3.45元，对应2021年3月30日收盘价的PE为98/65/46x","content_offset":["1743","1799"],"indicators":[{"indicator_name":"EPS","indicator_value":["1.62","1755","1759"],"indicator_element":{"时间":["21-23年","1745","1751"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}},{"indicator_name":"EPS","indicator_value":["2.45","1760","1764"],"indicator_element":{"时间":["21-23年","1745","1751"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}},{"indicator_name":"EPS","indicator_value":["3.45元","1765","1770"],"indicator_element":{"时间":["21-23年","1745","1751"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"34","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"对应2021年3月30日收盘价的PE为98/65/46x","content_offset":["1771","1799"],"indicators":[{"indicator_name":"估值","indicator_value":["98","1790","1792"],"indicator_element":{"时间":["2021年3月30日","1773","1783"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}},{"indicator_name":"估值","indicator_value":["65","1793","1795"],"indicator_element":{"时间":["2021年3月30日","1773","1783"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}},{"indicator_name":"估值","indicator_value":["46x","1796","1799"],"indicator_element":{"时间":["2021年3月30日","1773","1783"],"公司":["华熙生物","1729","1733"]},"indicator_supplement":{"属性":""}}]},{"id":"35","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"2020年实现营收26.33亿元","content_offset":["835","851"],"indicators":[{"indicator_name":"营业收入","indicator_value":["26.33亿元","844","851"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"36","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长39.63%","content_offset":["852","862"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["39.63%","856","862"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"37","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"扣非归母净利润5.68亿元","content_offset":["895","908"],"indicators":[{"indicator_name":"扣非归母净利润 ","indicator_value":["5.68亿元","902","908"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"38","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长0.13%","content_offset":["909","918"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["0.13%","913","918"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["2020年","835","840"]},"indicator_supplement":{"属性":""}}]},{"id":"39","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"Q4实现营收10.36亿元","content_offset":["919","932"],"indicators":[{"indicator_name":"营业收入","indicator_value":["10.36亿元","925","932"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"40","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长73.38%","content_offset":["933","943"],"indicators":[{"indicator_name":"营业收入同比","indicator_value":["73.38%","937","943"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"41","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"归母净利润2.08亿元","content_offset":["944","955"],"indicators":[{"indicator_name":"归母净利润","indicator_value":["2.08亿元","949","955"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"42","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长22.98%","content_offset":["956","966"],"indicators":[{"indicator_name":"归母净利润同比","indicator_value":["22.98%","960","966"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"43","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"扣非归母净利润1.94亿元","content_offset":["967","980"],"indicators":[{"indicator_name":"扣非归母净利润","indicator_value":["1.94亿元","974","980"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"44","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长25.38%","content_offset":["981","991"],"indicators":[{"indicator_name":"扣非归母净利润同比","indicator_value":["25.38%","985","991"],"indicator_element":{"公司":["华熙生物","1729","1733"],"时间":["Q4","919","921"]},"indicator_supplement":{"属性":""}}]},{"id":"45","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"润百颜/夸迪/米蓓尔/BM肌活品牌分别增长65.29%/513.29%/136.32%/45.71%至5.65/3.91/1.99/1.13亿元","content_offset":["2233","2305"],"indicators":[{"indicator_name":"主营业务收入同比","indicator_value":["65.29%","2254","2260"],"indicator_element":{"品牌":["润百颜","2233","2236"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}},{"indicator_name":"主营业务收入同比","indicator_value":["513.29%","2261","2268"],"indicator_element":{"品牌":["夸迪","2237","2239"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}},{"indicator_name":"主营业务收入同比","indicator_value":["136.32%","2269","2276"],"indicator_element":{"品牌":["米蓓尔","2240","2243"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}},{"indicator_name":"主营业务收入同比","indicator_value":["45.71%","2277","2283"],"indicator_element":{"品牌":["BM肌活","2244","2248"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}}]},{"id":"46","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"润百颜/夸迪/米蓓尔/BM肌活品牌分别增长65.29%/513.29%/136.32%/45.71%至5.65/3.91/1.99/1.13亿元","content_offset":["2233","2305"],"indicators":[{"indicator_name":"主营业务收入","indicator_value":["5.65","2284","2288"],"indicator_element":{"品牌":["润百颜","2233","2236"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}},{"indicator_name":"主营业务收入","indicator_value":["3.91","2289","2293"],"indicator_element":{"品牌":["夸迪","2237","2239"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}},{"indicator_name":"主营业务收入","indicator_value":["1.99","2294","2298"],"indicator_element":{"品牌":["米蓓尔","2240","2243"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}},{"indicator_name":"主营业务收入","indicator_value":["1.13亿元","2299","2305"],"indicator_element":{"品牌":["BM肌活","2244","2248"],"公司":["华熙生物","7344","7348"],"时间":["2020年","2859","2864"]},"indicator_supplement":{"属性":""}}]},{"id":"47","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"润百颜8月推出新品377小灯管精华次抛玻尿酸，与多个KOL合作，并在通过薇娅直播间打开知名度，新品上市后在8月和11月成为天猫旗舰销售额排名第一的产品，爬取的天猫数据显示377精华在两个月中分别实现销售额1890/3197万元","content_offset":["2392","2505"],"indicators":[{"indicator_name":"销售额","indicator_value":["1890","2494","2498"],"indicator_element":{"时间":["8月","2395","2397"],"品牌":["润百颜","2392","2395"],"公司":["华熙生物","7344","7348"]},"indicator_supplement":{"属性":""}},{"indicator_name":"销售额","indicator_value":["3197万元","2499","2505"],"indicator_element":{"时间":["11月","2448","2451"],"品牌":["润百颜","2392","2395"],"公司":["华熙生物","7344","7348"]},"indicator_supplement":{"属性":""}}]},{"id":"48","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"原料业务：毛利率水平最低，营收占比有所下降。公司通过不断科研构筑高壁垒并保持产品竞争力，毛利率为78.09%","content_offset":["4397","4451"],"indicators":[{"indicator_name":"毛利率","indicator_value":["78.09%","4445","4451"],"indicator_element":{"公司":["华熙生物","7344","7348"],"时间":["2020年","4318","4323"],"业务":["原料业务","4397","4401"]},"indicator_supplement":{"属性":""}}]},{"id":"49","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"同比增长1.97%","content_offset":["4452","4461"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["1.97%","4456","4461"],"indicator_element":{"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"],"业务":["原料业务","4397","4401"]},"indicator_supplement":{"属性":""}}]},{"id":"50","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"医药级透明质酸原料毛利率保持在90%左右","content_offset":["4465","4485"],"indicators":[{"indicator_name":"毛利率","indicator_value":["90%","4480","4483"],"indicator_element":{"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"],"业务":["医药级透明质酸原料","4465","4474"]},"indicator_supplement":{"属性":""}}]},{"id":"51","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"医疗终端业务：毛利率为84.55%","content_offset":["4488","4505"],"indicators":[{"indicator_name":"毛利率","indicator_value":["84.55%","4499","4505"],"indicator_element":{"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"],"业务":["医疗终端业务","4488","4494"]},"indicator_supplement":{"属性":""}}]},{"id":"52","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"功能性护肤品业务：毛利率为81.89%","content_offset":["4774","4793"],"indicators":[{"indicator_name":"毛利率","indicator_value":["81.89%","4787","4793"],"indicator_element":{"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"],"业务":["功能性护肤品业务","4774","4782"]},"indicator_supplement":{"属性":""}}]},{"id":"53","source_document":"华熙生物（688363）：收入表现更好，预期未来预期发布效率提高净利率.pdf","content":"润百颜/夸迪/米蓓尔/BM肌活品牌的毛利率分别同比提高+2.80%/+5.95%/-0.53%/+9.82%","content_offset":["4821","4875"],"indicators":[{"indicator_name":"毛利率同比","indicator_value":["+2.80%","4848","4854"],"indicator_element":{"品牌":["润百颜","4821","4824"],"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率同比","indicator_value":["+5.95%","4855","4861"],"indicator_element":{"品牌":["夸迪","4825","4827"],"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率同比","indicator_value":["-0.53%","4862","4868"],"indicator_element":{"品牌":["米蓓尔","4828","4831"],"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"]},"indicator_supplement":{"属性":""}},{"indicator_name":"毛利率同比","indicator_value":["+9.82%","4869","4875"],"indicator_element":{"品牌":["BM肌活","4832","4836"],"公司":["华熙生物","7344","7348"],"时间":["2020年","5233","5238"]},"indicator_supplement":{"属性":""}}]}]}